RBC Capital Reiterates Outperform on 89bio, Maintains $34 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams has reiterated his 'Outperform' rating on 89bio (NASDAQ:ETNB) and maintained a price target of $34.
September 22, 2023 | 2:21 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital has reiterated its 'Outperform' rating on 89bio and maintained a price target of $34, which could positively impact the stock in the short term.
Analyst ratings and price targets can significantly influence investor sentiment and stock prices. The reiteration of the 'Outperform' rating and maintenance of the $34 price target by RBC Capital indicates their continued confidence in 89bio, which could lead to increased investor interest and a potential rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100